Activity of novel antifungal compound APX001A against a large collection of Candida auris.
APX001A is an antifungal agent that targets a novel pathway-glycosylphosphatidylinositol glycolipid biosynthesis. It has been shown to be effective against a variety of fungal species, including Candida spp., Aspergillus spp. and other filamentous fungi. To determine the activity of APX001A against the emerging fungal pathogen Candida auris. APX001A was tested by broth microdilution against 100 geographically distinct isolates of C. auris. APX001A showed activity against all isolates, including some that were resistant to one or more antifungals, with MIC50 and MIC90 of 0.002 and 0.008 mg/L, respectively. These findings suggest that APX001A shows encouraging activity against the emerging fungal pathogen C. auris.